ADMET and DMPK  

Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs

Kin Tam

Abstract


The initial dose selection is one of the important steps for any investigative new drug (IND) entering the first clinical study in human. In this mini review, we will discuss the no observed adverse effect level (NOAEL) and the minimum anticipated biological effect level (MABEL) approaches for the estimations of first in human (FIH) dose. Particular attention will be placed on the development of FIH dose for oncology drugs.


Full Text:

PDF


DOI: http://dx.doi.org/10.5599/admet.1.4.10

Refbacks

  • There are currently no refbacks.


ISSN 1848-7718